Rockwell Medical Inc (RMTI) FinancialsRMTIRockwell Medical Inc

Rockwell Medical Inc (RMTI) generates its revenue primarily from Concentrate Products, which accounts for 100.0% of total sales, equivalent to $17.78M. Understanding this concentration is critical for investors evaluating how RMTI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Rockwell Medical Inc maintains a gross margin of 18.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.97%, while the net margin is -6.59%. These profitability ratios, combined with a Return on Equity (ROE) of -16.00%, provide a clear picture of how effectively RMTI converts its operational activities into shareholder value.

In the context of the broader market, RMTI competes directly with industry leaders such as MLSS and DRIO. With a market capitalization of $31.23M, it holds a leading position in the sector. When comparing efficiency, RMTI's gross margin of 18.24% stands against MLSS's 66.55% and DRIO's 61.66%. Such benchmarking helps identify whether Rockwell Medical Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenues, with Q2 2026 revenue at $17.78 million and a gross margin of 18.24%. However, it continues to report net losses, with a net income of -1.32 million in Q2 2026.